| scholarly article | Q13442814 |
| P2093 | author name string | Robert S Schwartz | |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1079-80 | |
| P577 | publication date | 2004-03-11 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Paul Ehrlich's magic bullets | |
| P478 | volume | 350 |
| Q35050207 | After Venus, mercury: syphilis treatment in the UK before Salvarsan. |
| Q34557365 | An Overview of Arsenic Metabolism and Toxicity |
| Q38724754 | Antibiotics: from prehistory to the present day. |
| Q36373103 | Antibody targeted drugs as cancer therapeutics |
| Q53739135 | Antibody-Drug Conjugates for Cancer Therapy. |
| Q47851750 | Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments |
| Q46209550 | Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. |
| Q26800175 | Antibody-drug conjugates as novel anti-cancer chemotherapeutics |
| Q99630424 | Antibody-drug conjugates: smart weapons against cancer |
| Q36825045 | Asthma treatment: 'magic bullets which seek their own targets'. |
| Q35827640 | Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms |
| Q38373185 | Current ADC Linker Chemistry |
| Q38842808 | Delivering therapeutics in peripheral artery disease: challenges and future perspectives |
| Q42293596 | Development of a facile antibody-drug conjugate platform for increased stability and homogeneity |
| Q36923799 | Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity |
| Q99410209 | Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates targeting Biofilm-associated Lectins of Pseudomonas aeruginosa |
| Q53311853 | Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress. |
| Q38101004 | Drugs in development for relapsing multiple sclerosis |
| Q90333773 | High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody-Drug Conjugate Aggregation and Drug Release |
| Q34262986 | History of antibiotics. From salvarsan to cephalosporins |
| Q44369173 | Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy |
| Q49831027 | Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays |
| Q92477344 | Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research |
| Q37184808 | Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency |
| Q92750453 | Increasing the Potential of the Auristatin Cancer-Drug Family by Shifting the Conformational Equilibrium |
| Q34235476 | Melanoma vaccines: mixed past, promising future |
| Q43742571 | Microfluidic assisted self-assembly of chitosan based nanoparticles as drug delivery agents |
| Q39017196 | Microfluidic-assisted self-assembly of complex dendritic polyethylene drug delivery nanocapsules |
| Q45435082 | New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling |
| Q95273167 | Novel antibody-drug conjugates for triple negative breast cancer |
| Q34512417 | Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. |
| Q28073074 | Personalized Medicine in Allergy |
| Q35189546 | Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite |
| Q37859634 | Places and chemistry: Strasbourg--a chemical crucible seen through historical personalities |
| Q89823337 | Rational design of block copolymer self-assemblies in photodynamic therapy |
| Q35639154 | Reporter phage and breath tests: emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy. |
| Q37593705 | Site-specific antibody drug conjugates for cancer therapy |
| Q50041898 | Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins |
| Q38663174 | Structure-guided design of a novel class of benzyl-sulfonate inhibitors for influenza virus neuraminidase |
| Q22241378 | Syphilis treatment: old and new |
| Q61809541 | Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells |
| Q22306413 | The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize |
| Q84560547 | The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma |
| Q96641056 | Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire |
| Q81939679 | [Immunmodulatory antibodies in the treatment of skin cancer] |
| Q64982978 | [The discovery of hypothalamic hormones and the development of antitumor analogs]. |
Search more.